We have summarized results indicating that inhibiting PAGE4 using small molecule inhibitors may be a novel therapeutic strategy for symptomatic BPH, and for low-risk, androgen-sensitive PCa, where it is highly upregulated. The gene discussed is PAGE4; the disease is benign prostatic hyperplasia.